In late 2024, the U.S. Food and Drug Administration proposed a rule that would have required cosmetic manufacturers to test talc products for asbestos using modern, highly sensitive detection methods—an approach that would have dramatically reshaped both consumer safety oversight and talc litigation nationwide. Just one year later, the FDA withdrew that proposal, leaving unresolved a debate that has been playing out for decades in courtrooms rather than regulatory agencies.

That debate centers on a product so familiar it rarely drew a second thought: cosmetic talc commonly sold as "baby powder." For decades, millions of Americans—overwhelmingly women—used talc daily as part of ordinary hygiene, applying it in small bathrooms with limited ventilation, breathing in airborne powder, or using it in the perineal area where particles could be ingested or migrate internally through the reproductive tract over time. No warning labels. No gloves. No masks. Just a trusted household product marketed as gentle, clean, and safe.

Plaintiffs in cosmetic talc cases allege that this daily ritual carried an invisible risk: that talc mined from asbestos-bearing geological formations was contaminated with trace asbestos fibers, which were released into the air during normal use and inhaled or ingested repeatedly over many years. According to plaintiffs, it is this cumulative, low-dose exposure—often beginning decades before diagnosis—that contributed to diseases such as mesothelioma and ovarian cancer.

How Plaintiffs Say They Know Asbestos Was There

The talc exposure theory does not rest on speculation. It rests on testing.

Over the past several decades, independent laboratories, government agencies, and litigants have tested cosmetic talc products using increasingly sensitive analytical techniques. Those tests have shown that some cosmetic talc products—including products manufactured by major household brands such as Johnson & Johnson have, at times, contained detectable asbestos fibers.

The critical point is not that every container of talc contained asbestos. It is that asbestos contamination occurred intermittently and unpredictably, depending on the mine, the seam, the batch, and the testing method used. That variability is exactly what plaintiffs say made the risk so dangerous: consumers had no way to know when a given bottle was contaminated, and manufacturers allegedly failed to warn or adequately screen for that risk.

To identify asbestos in talc, plaintiffs rely primarily on transmission electron microscopy (TEM)—a method capable of detecting extremely thin asbestos fibers embedded in fine powder. TEM has been used for decades in environmental and occupational settings and can identify asbestos fibers that are invisible to older screening tools. Plaintiffs argue that this sensitivity matters because talc is finely milled and any asbestos present is likely to be small, sparse, and easily missed by less sensitive methods.

How Defendants Have Responded

Defendants do not dispute that asbestos causes mesothelioma or that talc and asbestos can occur in close proximity geologically. Instead, their response has focused on challenging the significance of what testing reveals.

Manufacturers argue that cosmetic talc was asbestos-free, that positive test results reflect contamination from the testing process itself or from ubiquitous “background” asbestos present in the environment, and that highly sensitive methods like TEM detect fibers that are biologically insignificant. They also contend that some fibers identified by plaintiffs' experts are not regulated asbestos but non-asbestiform mineral fragments.

For years, this disagreement has played out not in regulatory forums, but in courtrooms—through discovery disputes, expert depositions, and Daubert motions challenging the reliability of plaintiffs' testing protocols, counting rules, and interpretations. The result has been a patchwork of rulings, with juries often left to decide which experts to believe.

Why the FDA's Proposed Rule Was Such a Big Deal

That longstanding equilibrium was disrupted in late 2024, when the FDA proposed a rule requiring standardized testing methods to detect asbestos in talc-containing cosmetic products. In one fell swoop, the proposed rule would have undercut several of the defense arguments that have dominated talc litigation for decades.

First, the rule would have required manufacturers and talc suppliers to use a combined analytical approach, including both polarized light microscopy (PLM) and confirmatory transmission electron microscopy (TEM). By doing so, the FDA would have effectively rejected the notion that less sensitive screening methods are sufficient to rule out asbestos in cosmetic talc.

Second, the proposed rule did not establish a “safe” level of asbestos. Instead, it treated any detectable asbestos as grounds for regulatory concern. That approach would have directly challenged the defense position that trace or background exposures are irrelevant or harmless from a consumer safety standpoint.

Third, by formally endorsing TEM as a necessary part of asbestos detection, the FDA would have validated testing methodologies that defendants have long attacked as unreliable or overly aggressive. Methods that defense counsel have spent years challenging in Daubert motions would, under the rule, have become the government's chosen tools for determining whether talc is contaminated.

The Withdrawal—and the Lingering Implications

In late 2025, the FDA withdrew the proposed rule, citing unresolved scientific, technical, and legal issues raised during the public comment process. The agency emphasized that it intends to re-propose a rule to meet its statutory obligations under the Modernization of Cosmetics Regulation Act.

For defendants, the withdrawal preserved familiar ground. The absence of a binding federal standard means that arguments about testing sensitivity, background exposure, and methodological overreach remain available. For plaintiffs, the withdrawal was disappointing—but it was not a repudiation of the science underlying their claims. The FDA did not conclude that asbestos contamination is imaginary or that TEM is invalid. It concluded that the issues are complex and consequential enough to require further deliberation.

Most people who used talc did so exactly as intended—daily, over years, in confined spaces, without any reason to suspect risk. The litigation that followed has forced uncomfortable questions: What level of contamination is acceptable in consumer products? How sensitive should testing be? And who bears the risk when hazards are invisible, cumulative, and slow to manifest?

The FDA's proposed rule briefly suggested a clear answer. Its withdrawal leaves those questions where they have been for years—in the hands of juries and judges.